Galera Therapeutics, Inc. (GRTX)
USD 0.02
(8.11%)
USD 0.02
(8.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -46.69 Million USD | 8.85% |
| 2022 | -50.6 Million USD | 29.4% |
| 2021 | -72.55 Million USD | -2.84% |
| 2020 | -69.01 Million USD | -39.18% |
| 2019 | -50.69 Million USD | -115.5% |
| 2018 | -23.52 Million USD | 1.24% |
| 2017 | -23.81 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.05 Million USD | 11.16% |
| 2024 Q1 | -4.56 Million USD | 7.92% |
| 2023 Q3 | -10.66 Million USD | 34.58% |
| 2023 FY | - USD | 8.85% |
| 2023 Q4 | -4.96 Million USD | 53.48% |
| 2023 Q2 | -16.3 Million USD | -17.43% |
| 2023 Q1 | -13.88 Million USD | -5.49% |
| 2022 Q4 | -13.15 Million USD | -3.11% |
| 2022 Q2 | -11.85 Million USD | 9.57% |
| 2022 Q1 | -13.1 Million USD | 6.56% |
| 2022 FY | - USD | 29.4% |
| 2022 Q3 | -12.76 Million USD | -7.65% |
| 2021 Q2 | -20.98 Million USD | -20.88% |
| 2021 FY | - USD | -2.84% |
| 2021 Q3 | -20.19 Million USD | 3.76% |
| 2021 Q4 | -14.03 Million USD | 30.51% |
| 2021 Q1 | -17.35 Million USD | 8.38% |
| 2020 Q4 | -18.94 Million USD | -20.3% |
| 2020 FY | - USD | -39.18% |
| 2020 Q3 | -15.74 Million USD | 8.8% |
| 2020 Q2 | -17.26 Million USD | 3.1% |
| 2020 Q1 | -17.81 Million USD | -10.21% |
| 2019 Q1 | -9.89 Million USD | -18.04% |
| 2019 FY | - USD | -115.5% |
| 2019 Q4 | -16.16 Million USD | -30.86% |
| 2019 Q3 | -12.35 Million USD | -15.56% |
| 2019 Q2 | -10.69 Million USD | -8.07% |
| 2018 Q2 | -4.96 Million USD | 0.0% |
| 2018 Q1 | -4.96 Million USD | 0.0% |
| 2018 Q3 | -5.26 Million USD | -5.9% |
| 2018 FY | - USD | 1.24% |
| 2018 Q4 | -8.38 Million USD | -59.33% |
| 2017 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -10338.818% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -58.246% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 59.061% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -196.25% |
| Better Therapeutics, Inc. | -38.26 Million USD | -22.032% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -22.023% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -161.045% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -38.416% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -39.91% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 56.094% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -5011.481% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -43.747% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -721.5% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -186.433% |
| Molecular Templates, Inc. | 1.43 Million USD | 3365.175% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -236.516% |
| NexImmune, Inc. | -28.16 Million USD | -65.765% |
| Orgenesis Inc. | -60.71 Million USD | 23.1% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 8.972% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -63499.215% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -189.199% |
| Scopus BioPharma Inc. | -11.71 Million USD | -298.629% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 91.352% |
| Statera Biopharma, Inc. | 38.93 Million USD | 219.923% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -578.268% |
| Trevena, Inc. | -35.28 Million USD | -32.317% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -83202.706% |
| Vaccinex, Inc. | -19.74 Million USD | -136.439% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -4359.693% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 0.363% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -542.874% |